Výsledky vyhledávání - "Masaru Mutoh"

Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus

Autor: Nobuo Mizui, Shi Chen, Yoshishige Samukawa, Masaru Mutoh

Publikováno v: Biological & Pharmaceutical Bulletin. 40:1207-1218

Luseogliflozin is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by promoting urinary glucose excretion (UGE). A clinical pharmacology study conducted in Japanese patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f43100df39536de2a1eb95cc3ad1de6
https://doi.org/10.1248/bpb.b16-00998

Zobrazit plný text záznamu

Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers

Autor: Hironori Yamasaki, Hirotaka Watase, Noriko Takayama, Tomohiro Sugimoto, Fumihiko Sato, Aya Shinfuku, Sota Kato, Takumi Numazaki, Toshiharu Shimazaki, Jinsei Maruyama, Masaru Mutoh, Masanori Fujiwara, Yasunori Kawakita

Publikováno v: American journal of nephrology. 48(3)

Background: TP0463518 is a novel hypoxia-inducible factor prolyl hydroxylase inhibitor developed to aid in the treatment of anemia associated with chronic kidney disease (CKD) and is expected to increase erythropoietin (EPO) derived from liver. Two p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13160d21eb0c219172a44e552b18a22
https://pubmed.ncbi.nlm.nih.gov/30176654

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání